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ABSTRACT
Post-translational modifications directly control protein activity and,
thus, they represent an important means to regulate the responses of
cells to different stimuli. Protein SUMOylation has recently been
recognised as one such modification, and it has been associated with
various diseases, including different types of cancer. However, the
precise way that changes in SUMOylation influence the tumorigenic
properties of cells remains to be fully clarified. Here, we show that
blocking the SUMO pathway by depleting SUMO1 and UBC9, or by
exposure to ginkgolic acid C15:1 or 2-D08 (two different SUMOylation
inhibitors), induces cell death, also inhibiting the invasiveness of
tumour cells. Indeed, diminishing the formation of SUMO1 complexes
induces autophagy-mediated cancer cell death through increasing
the expression of Tribbles pseudokinase 3 (TRIB3). Moreover, we
found that blocking the SUMO pathway inhibits tumour cell invasion
by decreasing RAC1 SUMOylation. These findings shed new light on
the mechanisms by which SUMO1 modifications regulate the
survival, and the migratory and invasive capacity of tumour cells,
potentially establishing the bases to develop novel anti-cancer
treatments based on the inhibition of SUMOylation.
KEY WORDS: SUMO modification, Rho-GTPase, Breast cancer,
Autophagy, Ginkgolic acid, TRIB3
INTRODUCTION
The post-translational addition of the small ubiquitin-related
modifier (SUMO) peptide is now established as one of the key
regulatory modifications in eukaryotic cells. SUMOylation involves
the reversible binding of a SUMO peptide to a lysine residue in the
target protein and, to date, four different SUMO isoforms have been
identified: SUMO1, SUMO2 and SUMO3 (denoted SUMO2/3
because they have a high degree of similarity), and SUMO4 (Saitoh
and Hinchey, 2000). The addition of these peptides is mediated by
an enzyme cascade that includes an activating enzyme (heterodimer
SAE1/2), an E2-conjugating enzyme (UBC9) and an E3 ligase
(RANBP2 from the SIZ/PIAS family and members of the ZNF451
family) (Hay, 2005; Pichler et al., 2017), and the substrates can be
modified by adding a single SUMO moiety, multiple SUMOs or
SUMO chains (Pichler et al., 2017). In addition, specific SUMO-
modified proteins can be deSUMOylated by a group of sentrin/
SUMO-specific proteases (SENPs) (Hay, 2007).
The conjugation of a SUMO moiety affects proteins distinctly,
modifying their activity, subcellular localization or stability. Many
cellular pathways are influenced by reversible SUMOylation, such
as those that influence chromatin organization, transcription,
DNA repair, macromolecular assembly, protein homeostasis,
trafficking and signal transduction (Geiss-Friedlander and
Melchior, 2007). Failure to SUMOylate specific targets and the
global misregulation of SUMOylation has been linked to different
diseases, including cancer and heart failure (Flotho and Melchior,
2013). Therefore, interfering with the SUMOylation machinery
could represent a novel therapeutic approach in the management of
some diseases.
Ginkgolic acids (GAs) are a group of alkyl phenols found in
crude extracts of Ginkgo biloba leaves, an ancient gymnosperm
species now distributed globally (Mahadevan and Park, 2008).
There are several molecular species of GA; these have a different
length for their alkyl group within the main structure of the molecule
(C13:0, C15:1 and C17:1). GAs display anti-cancer activity, and in
several studies GA has been shown to inhibit the growth and
invasion of a number of cancer cell types, including pancreatic,
liver, pharyngeal and colon cancer (Qiao et al., 2017). While the
mode of action of these compounds is still poorly understood, GA
C15:1 has been shown to directly bind to E1 activating enzymes and
impair the formation of the E1–SUMO1 intermediate (Fukuda et al.,
2009). However, it remains to be clarified whether the anti-cancer
activity of GAs depends on inhibition of the SUMOmachinery or if
additional mechanisms are involved in this effect.
RAC1 is a member of the Rho family of small GTPases that act as
molecular switches to control a wide array of cellular events. RAC1
activity can modulate the cytoskeleton, which is critical for a
number of cellular activities such as phagocytosis, mesenchymal-
like migration, axon growth, adhesion, cell differentiation and cell
death mediated by reactive oxygen species (ROS) (Acevedo and
Gonzalez-Billault, 2018). RAC1 also plays an important role in
moderating other signalling pathways that influence cell growth and
the cell cycle (Mettouchi et al., 2001; Olson et al., 1995), the
formation of cell–cell adhesions (Daugaard et al., 2013) and contact
inhibition (Nobes and Hall, 1995). These RAC1-mediated activities
appear to be central to the processes that underlie malignantReceived 8 May 2019; Accepted 18 September 2019
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transformation, including tumorigenesis, angiogenesis, invasion
and metastasis (Mack et al., 2011).
The RAC1 GTPase binds to either GTP or GDP, the exchange of
which controls its activation. RAC1 is inactive in the GDP-bound
state and it is activated upon exchange of its GDP for GTP, enabling
downstream signalling to proceed. RAC1 activity can be regulated
through its association with several guanine nucleotide-exchange
factors (GEFs) and GTPase-activating proteins (GAPs), these
controlling the cycling between the GDP- and GTP-bound states.
Furthermore, post-translational modifications (PTMs) of RAC1 can
also regulate its activity. As such, modification of the C-terminal
CAAX motif in RAC1 through the addition of either farnesyl or
geranylgeranyl isoprenoid lipids increases its hydrophobicity,
facilitating both its membrane localization and activation (Mack
et al., 2011). Ubiquitin-like (UBL) modifications of RAC1 have
also been shown to regulate its activity, including ubiquitylation
(Castillo-Lluva et al., 2013) and SUMOylation (Castillo-Lluva
et al., 2010), adding further complexity to the regulation of RAC1
signalling.
We observed RAC1 GTPase SUMOylation (RAC1-SUMO1)
when the epithelial to mesenchymal transition (EMT) was induced
by hepatocyte growth factor (HGF) (Castillo-Lluva et al., 2010).
EMT involves changes in gene expression, and it is associated with
a loss of cell polarity and an increase in cell invasiveness (Brabletz
et al., 2018). The RAC1 GTPase plays an important role in the EMT
programme (Ungefroren et al., 2018) and significantly, RAC1
SUMOylation is necessary for optimal cell migration when non-
tumorigenic cells undergo EMT. Similarly, cancer cells also induce
the EMT programme when they metastasize and invade other
tissues (Brabletz et al., 2018), such that RAC1 SUMOylation could
also play an important role in this context.
Here, we demonstrate that blockade of the SUMO1 conjugation
pathway inhibits two of the cellular programmes that are activated
during tumorigenesis, cancer cell survival and invasiveness. These
effects are due to the activation of two independent mechanisms: the
induction of autophagy-mediated cancer cell death through
enhanced TRIB3 expression, and inhibition of RAC1-dependent
cancer cell migration and invasion. Tumour cell invasion and
metastasis are thought to be responsible for 90% of cancer-
associated deaths. Thus, inhibiting SUMOylation could represent a
novel therapeutic strategy to convert cancer from a mortal into a
chronic disease.
RESULTS
Blocking the SUMO pathway inhibits cell viability in breast
and prostate cancer cells
As a first approach to investigate the effect of inhibiting the SUMO
pathway on the tumorigenic properties of cancer cells, we analysed
the effects of the natural compound GAC15:1 (hereafter referred to
as GA), which blocks the SUMO pathway by inhibiting the
formation of the E1–SUMO1 intermediate (Fukuda et al., 2009).
Exposure of luminal (MCF7), triple-negative (MDA-MB-231) and
HER2+ (BT474) breast cancer cells to a relatively low dose of GA
(10 µM) reduced the overall protein SUMOylation in these cells
by ∼40–50% (Fig. 1A). Moreover, this reduction in SUMO
conjugation was more pronounced when these cells were exposed
to a higher dose of GA (20 µM, Fig. S1A). When we then tested the
effect of this compound on the survival of the different breast and
prostate cancer cell lines, exposure to GA clearly diminished their
viability in a dose-dependent manner (Fig. 1B; Fig. S1B). Hence,
the effect of GA on cell viability appears to be common to different
types of cancer cells. We identified the IC50 of GA as 10 µM in
MDA-MB-231 cells and 20 µM in MCF7 cells (the concentration
that reduced the viability of cells by 50% compared with the control
after a 2 day treatment; Fig. 1C; Fig. S1C). Accordingly, to study the
mechanisms underlying these effects, we used sub-maximal doses
of GA (10 µM) to enhance specificity and to avoid any potential
toxicity associated with the excessive loss of protein SUMOylation.
When we assessed the proliferation of cancer cells through the
expression of the Ki67 marker, exposure to GA (10 µM) provoked a
decrease in proliferation (Fig. 1D,E) and it reduced the levels of
JUN (Fig. S1D), a transcription factor associated with the
proliferation of breast cancer cells (Vleugel et al., 2006).
To confirm that the effect of GA observed was due to the
inhibition of SUMOylation, we used a different SUMO1 inhibitor
(2-D08) that blocks the transfer of SUMO from the E2 enzyme
(UBC9) thioester conjugate to the substrate (Choi et al., 2018; Kim
et al., 2014). Exposure of the triple-negative cell line (MDA-MB-
231) to a relatively low dose of GA and 2-D08 reduced overall
protein SUMOylation (Fig. 1F). While GA reduced the intensity of
SUMO-conjugated proteins at 24 h, 2-D08 achieved a similar effect
after a 48 h exposure. Accordingly, no differences in cell
proliferation were observed in the presence of 2-D08 after 24 h,
although cell viability was compromised after 48 h in the presence
of this SUMO1 inhibitor (Fig. 1G,H).
To further confirm that SUMO1-mediated SUMOylation was
responsible for the loss of cell viability observed in the presence of
GA, we used a specific pool of siRNAs to deplete SUMO1 over
72 h (Fig. 1I) in the triple-negativeMDA-MB-231 breast cancer cell
line, a particularly aggressive subtype of breast cancer. As a result,
we found that the depletion of SUMO1 reduced cell viability
(Fig. 1J) and impaired cell proliferation (Fig. 1K,L).
Together, these results support the notion that inhibition of
protein SUMOylation by using genetic or pharmacological
approaches reduces the viability and the proliferation of cancer cells.
Pharmacological inhibition of the SUMO pathway induces
autophagy-mediated cancer cell death
To understand how the SUMO pathway might affect the viability of
cancer cells, we analysed the mechanisms activated in response to
GA in the triple-negative MDA-MB-231 breast cancer cell line.
We measured the rate of MDA-MB-231 apoptosis after a 48 h
exposure to GA (10 µM), a time point at which cell viability was
compromised (Fig. 1B). By using an Annexin V-FITC and
propidium iodide (PI) staining assay, GA was seen to increase the
proportion of apoptotic cells after 48 h of treatment (Fig. 2A,B) and
indeed, an increase in cleaved caspase-3 and cleaved PARPwas also
evident in Western blots and by immunofluorescence after a 48 h
exposure to GA (Fig. 2C–G). Similar results were also obtained
with the SUMO inhibitor 2-D08 (Fig. S2A). Furthermore, we
identified an increase in the apoptotic protein BAX at early time
points (12 and 24 h, Fig. 2H), suggesting that early activation of
the intrinsic mitochondrial pathway might be involved in the
stimulation of apoptosis by GA.
We then investigated the mechanisms that might trigger this
apoptosis at earlier time points, as other compounds have already
been seen to promote apoptotic cancer cell death by stimulating
autophagy (Fulda and Kögel, 2015; Salazar et al., 2009b).
Autophagy is an essential homeostatic process that facilitates the
transport of cellular components to the lysosomal degradation
pathway. Depending on the cell context, stimulating autophagy can
produce protective or cytotoxic effects (Wilde et al., 2018). We
assessed whether the stimulation of autophagy might reduce tumour
cell viability in a manner similar to that observed upon SUMO
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inhibition with GA. A 24 h exposure to GA triggered the
accumulation of LC3II (the lipidated and autophagosome-
associated form of LC3 family proteins), as assessed by western
blotting, in both breast and prostate cancer cells, and as also evident
in immunofluorescence analyses (Fig. 2I–L; Fig. S2B–D). At this
time point, no change in cell viability had yet been observed.
Similar results were also obtained with the SUMO inhibitor 2-D08
(Fig. S2E–G).
Fig. 1. GA treatment compromises the viability of breast cancer cells. (A) Expression of SUMO-conjugated proteins (nSUMO1) in different molecular
subtypes of breast cancer cells: luminal (MCF7), triple-negative (MDA-MB-231) and HER2+ (BT474) treated with GA (10 µM) for 24 h and analysed by
immunoblotting (12% acrylamide gel). (B) MCF7, MDA-MB-231 and BT474 breast cancer cell lines were treated with various concentrations of GA and their cell
viability was assessed in an MTT assay: *P≤0.001; **P≤0.0001; n.s., not significant versus non-treated cells (two-way ANOVA). Turkey′s multiple comparisons
shows statistical significant differences in all conditions apart from 10 µM GA at 24 h. (C) Number of MDA-MB-231 cells after 2 days of treatment with different
concentrations of GA relative to the control (t=0 h treatment). (D) Representative image of immunohistochemical evaluation of Ki-67 expression in MDA-MB-231
tumour cells and (E) the percentage of Ki-67-positive cells. (F) Expression of SUMO-conjugated proteins (nSUMO1) inMDA-MB-231 cells exposed to GA (10 µM)
or 2-D08 (20 µM) for different times and analysed by immunoblotting (12% acrylamide gel). (G) Number of MDA-MB-231 cells after 2 days of treatment with
different concentrations of 2-D08 relative to the controls (t=0 h treatment). (H) Percentage of Ki-67-positive MDA-MB-231 cells after 2-D08 treatment for 24 h.
(I) SUMO-conjugated proteins in MDA-MB-231 control and SUMO1-depleted cells analysed by immunoblotting (12% acrylamide gel). (J) The viability of
MDA-MB-231 SUMO1-depleted cells was evaluated with an MTT assay at 72 h post-depletion. (K) Representative immunofluorescence images of MDA-MB-231
control and SUMO1-depleted tumour cells stained for Ki-67 expression and (L) the percentage of Ki-67-positive cells. All experiments were performed
at least three times and the data are the mean±s.e.m. of three independent experiments. Scale bars: 200 μm.
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It is known that LC3 lipidation (to give LC3II) and its
accumulation can be due to both the induction and blockade of
autophagy (Klionsky et al., 2016). Pharmacological inhibition of
the final step of autophagosome degradation (using E64d and
pepstatin-A) led to the accumulation of more LC3II, indicating
that GA activated autophagy rather than blocking it (Fig. 2M,N).
Fig. 2. GA treatment induces autophagy-mediated cell death in breast cancer cells. (A) Representative flow cytometry results of Annexin V-FITC/propidium
iodide (PI) staining showing the level of MDA-MB-231 cell apoptosis after GA treatment for 48 h (0, 10 μM). (B) Quantification of early apoptotic rate measured as
the percentage of Annexin V-positive and PI-negative cells (bottom right quadrant in A) (Student’s t-test). (C) Representative images of cleaved caspase-3
(C3) immunostaining in cells at 48 h and (D) the percentage of active caspase-3-stained cells at different time points. (E) The level of active caspase-3 in MDA-
MB-231 cells treated with GA (10 µM) as determined by immunoblotting. (F) Quantification of results in E as determined by densitometry analysis using ImageJ
software. (G) The effect of GA on cleaved PARPand (H) BAX at the time points indicated. (I) Representative images of LC3 immunostaining and (J) the proportion
of cells with LC3 dots relative to the total number of cells after a 24 h treatment. (K) The effect of GA (10 µM) on LC3 lipidation in MDA-MB-231 cells.
(L) Densitometric quantification of results from K using ImageJ software. (M) Effect of GA on LC3 lipidation in MDA-MB-231 cells in the presence of a combination
of the lysosomal protease inhibitor E64d and Pepstatin-A at 24 h. (N) Densitometry of results from M for at least three different experiments as quantified with
ImageJ software of (ANOVA test and Dunnett’s multiple comparisons test). (O) Effect of GA on the expression markers of autophagy as determined by qRT-PCR
12 h after treatment. RQ, relative quantification normalized to vehicle. (P) MDA-MB-231 breast cancer cells were treated with GA (10 µM) and a combination of
pepstatin-A and E64d for 48 h, and cell viability was assessed with an MTT assay after 48 h. (Q) Quantification of rate of early MDA-MB-231 cell apoptosis
after GA treatment and a combination of Pepstatin-A and E64d for 48 h (ANOVA test and Dunnett’s multiple comparisons test). (R) Activation of apoptosis
assessed through the level of cleaved PARP in MEF Atg5-WT or Atg5-KO cells in the presence of GA for 48 h. *P≤0.05, **P≤0.01.; n.s non-significant. All
experiments were performed at least three times and the data are the mean±s.e.m. of three independent experiments. Scale bars: 200 μm.
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Furthermore, shorter exposures to GA or 2-D08 induced the
expression of regulators of autophagy, such as BECN1, ATG5,
ATG1, ATG7 or AMBRA1 (Fig. 2O; Fig. S2H,I). Importantly,
there was no decrease in cell viability when MDA-MB-231 cells
were treated with GA, E64d and pepstatin-A (Fig. 2P), and the
increase in apoptosis evoked by GA was also prevented (Fig. 2Q).
Moreover, genetic depletion of three different key autophagy
regulatory genes (ATG5, BECN1 and AMBRA1) appeared to rescue
the apoptosis of these cells upon exposure to GA or 2-D08 (Fig. 2R;
Fig. S2J–L).
Together, these observations support the idea that inhibiting
SUMOylation induces autophagy-dependent cell death in breast
cancer cell lines.
Pharmacological inhibition of the SUMO pathway induces
the upregulation of the autophagy modulator TRIB3
Several anti-cancer agents that stimulate autophagy-dependent cell
death produce their effects by upregulating Tribbles pseudokinase-3
(TRIB3), including natural compounds of lipid origin that exhibit
structural similarities to GA (Erazo et al., 2016; Salazar et al.,
2009a; Vara et al., 2011). TRIB3 is an upstream regulator of the
mammalian target of rapamycin complex 1 (mTORC1) (Salazar
et al., 2015), the inhibition of which is considered to be the main
mechanism triggering autophagy in many cell settings (Mizushima
et al., 2008). Thus, we asked whether the stimulation of autophagy-
mediated cell death through pharmacological blockade of the
SUMO pathwaymight be related to changes in the expression of this
protein. Exposure to GA increased the levels of TRIB3 in breast
and prostate cancer cell lines (Fig. 3A,B; Fig. S3A), as did exposure
to the 2-D08 SUMO inhibitor (Fig. 3C,D). Therefore, we
hypothesized that the upregulation of TRIB3 might be the
primary event leading to autophagy-mediated cell death in
response to pharmacological inhibition of the SUMO pathway. In
fact, stable knockdown of TRIB3 expression in MDA-MB-231 cells
rendered these cells more resistant to GA-induced autophagy and
cell death (Fig. 3E,F), preventing the accumulation of the cleaved
forms of caspase-3 and PARP (two well established read-outs of
apoptosis) (Fig. 3G,H).
Hence, these observations led us to conclude that TRIB3
induction is involved in the stimulation of autophagy-mediated
apoptotic cell death upon pharmacological inhibition of the SUMO
pathway.
Genetic inhibition of SUMO1, but not of SUMO2/3, induces
TRIB3 upregulation and autophagy-mediated cancer cell
death
To verify that the above-described effects were based on the
inhibition of SUMO1, we knocked down SUMO1 expression in
MDA-MB-231 cells by using a pool of 3 SUMO1-selective
siRNAs. After a 72-h treatment, we found that the depletion of
SUMO1 increased the accumulation of LC3 dots (reflecting the
presence of autophagosomes in the cell), as well as the LC3II
accumulated in these cells (Fig. 4A–D). Furthermore, we found that
SUMO1 depletion induced a clear TRIB3 upregulation in MDA-
MB-231 cells (Fig. 4E,F). Similar results were obtained when we
used a different pool of two SUMO1-selective siRNAs (Fig. S3B) or
when we depleted the expression of the E2–SUMO ligase, UBC9
(Fig. 4J). Moreover, we observed an increase in cell death and
apoptosis after a 5 day depletion of SUMO1 that was prevented
when the last step of autophagic degradation was pharmacologically
Fig. 3. GA upregulates TRIB3 expression.
(A) MDA-MB-231 cells were treated with GA
(10 µM) at different time points and the TRIB3
protein was then analysed by immunoblotting.
(B) Densitometry of results in A as determined with
ImageJ software. (C) MDA-MB-231 cells were
treated with 2-D08 (20 µM) and the levels of the
TRIB3 protein was analysed at different time points
by immunoblotting. (D) Densitometry of results in C
as determined the ImageJ software. (E) MDA-MB-
231 control (ShC) and TRIB3-depleted (ShTRIB3)
cells were treated for 48 h with GA (10 µM) and cell
viability was determined with an MTT assay
(ANOVA test and Dunnett’s multiple comparisons
test). (F) LC3 lipidation in MDA-MB-231 control and
TRIB3-depleted cells treated for 24 h with GA was
assessed by immunoblotting. (G) Activation of
apoptosis as determined through assessment of the
level of active caspase-3 or (H) cleaved PARP in
immunoblots of MDA-MB-231 control and TRIB3-
depleted cells treated for 48 h with GA. All the
experiments were performed at least three times
and the data are the mean±s.e.m. of three
independent experiments. *P≤0.05.
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blocked with E64d and pepstatin-A (Fig. 4G–I). By contrast, no
differences were observed after SUMO2/3 depletion on TRIB3
expression, autophagy or apoptosis (Fig. 4K–M).
Taken together, these findings support the idea that
pharmacological or genetic inhibition of the SUMO1 pathway
activates autophagy-mediated cancer cell death.
Blockade of the SUMO1 pathway abrogates breast cancer
cell invasion via inhibition of RAC1 SUMOylation
Protein SUMOylation is thought to regulate cell migration and thus,
we decided to assess whether blocking the SUMO pathway might
also affect the invasive capacity of cancer cells. In accordance with
this hypothesis, exposure to GA under conditions that did not affect
Fig. 4. SUMO1 depletion induces autophagy and TRIB3 expression. (A) Representative images of LC3 immunostaining and (B) the percentage of cells with
LC3 dots relative to the total number of cells. (C) The effect of 72 h SUMO1 depletion on LC3 lipidation in MDA-MB-231 cells. (D) Densitometry quantification of
results from C as determined with ImageJ software. (E) TRIB3 protein levels were analysed by immunoblotting of SUMO1-depleted MDA-MB-231 cells.
(F) Densitometry quantification of results from E as determined using ImageJ software. (G) MDA-MB-231 control and SUMO1-depleted cells were treated for
24 h with E64d and Pepstatin-A, and cell viability was assessed with an MTT assay. (H) Activation of apoptosis (levels of cleaved PARP) was assessed by
immunoblotting in MDA-MB-231 SUMO1-depleted cells in the presence of E64d and Pepstatin-A. (I) Densitometry quantification results from H as determined
using ImageJ software. (J) The activation of autophagy (levels of LC3II, TRIB3) and apoptosis (levels of cleaved PARP) was analysed inMDA-MB-231 control and
UBC9-depleted cells. (K) Expression of SUMO2/3-conjugated proteins (nSUMO2/3) in MDA-MB-231 control and SUMO2-depleted cells were analysed by
immunoblotting (12% acrylamide gel). (L) The activation of autophagy (levels of LC3II, TRIB3) and apoptosis (levels of cleaved PARP) was analysed inMDA-MB-
231 control and SUMO2-depleted cells. (M) Densitometry results from L as determined using ImageJ software. All experiments were performed at least three
times and the data are the mean±s.e.m. of three independent experiments. Scale bar: 200 μm. *P≤0.05; n.s., not significant.
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cell viability (10 µM GA for 24 h) did inhibit breast cancer cell
invasion and migration by more than 50% (Fig. 5A), as did genetic
depletion of SUMO1 and UBC9 (Fig. 5B–E; Fig. S4B).
The GTPase RAC1 plays a crucial role in regulating cell
migration, and it has been implicated in cancer cell progression.
Likewise, increased expression of this GTPase is associated with a
poor prognosis in different cancer types (Mack et al., 2011).
Moreover, we previously showed that RAC1 is SUMOylated in
response to stimuli that trigger cell migration (Castillo-Lluva et al.,
2010). When we assessed whether the inhibition of cell invasion
triggered by blocking the SUMO pathway involves a dampening of
RAC1 activation, we found that GA did indeed inhibit RAC1
activity (RAC1-GTP) (Fig. 5F,G). Furthermore, breast cancer cells
treated with GA acquired a non-migratory phenotype and the
changes in the cytoskeleton of these cells resembled those observed
in cells when RAC1 signalling was abrogated. Significantly, this
effect was even more pronounced after 48 h in the presence of GA
(Fig. 5H).
Consequently, we analysed whether the reduction in RAC1
activity and in the invasive capacity of breast cancer cells induced by
GAwas dependent on the reduction in RAC1 SUMOylation. To test
this hypothesis, we first confirmed that GA reduced RAC1
SUMOylation (Fig. 5I). Subsequently, to validate the functional
consequences of this effect, we transfected MDA-MB-231 breast
cancer cells with plasmids expressing GFP, GFP-tagged wild-type
RAC1 (GFP–RAC1) or a fusion protein containingGFP and a RAC1
chimaera that mimics RAC1 SUMOylation (GFP–SUMO1–RAC1)
and, therefore, cannot be de-SUMOylated or be affected by GA.We
then examined the effect of exposing these cells to GA. The
expression of GFP–SUMO1–RAC1 but not that of wild-type RAC1
re-established the invasive capacity of these breast cancer cells upon
exposure to GA (Fig. 5J–L), as well as their migratory phenotype as
assessed by the capacity to form lamellipodia and ruffled structures
in the proximity of the plasma membrane (Fig. 5M,N). By contrast,
expression of GFP–SUMO1–RAC1 did not affect the decrease in
cell viability evoked by GA (Fig. 5O). Together, these observations
support the notion that inhibiting protein SUMOylation abrogates
the migratory and invasive capacity of breast cancer cell lines by
inhibiting RAC1 SUMOylation.
GA inhibits the growth of breast cancer xenografts, activates
the autophagy-mediated cancer cell death pathway and
inhibits RAC1 in vivo
To investigate the relevance of our findings in vivo, we examined the
effect of administering GA to athymic mice in which a tumour
xenograft had been generated by subcutaneous injection of MDA-
MB-231 cells into their right flank. Treatment with GA led to a
dramatic reduction in the growth of these tumours (Fig. 6A;
Fig. S4C). When the histology of these tumours was evaluated
following haematoxylin-eosin (HE) staining, the tumours treated
with GA contained areas rich in necrotic and apoptotic tissue, with a
lower mitotic index than the control xenografts (Fig. 6B).
Interestingly, PCNA staining revealed that there was a significant
decrease in proliferation in the tumours exposed to GA relative to
the controls (Fig. 6C,D), consistent with the lower mitotic index
in the HE stained tissue. Moreover, immunofluorescence and
immunoblotting on the final day of treatment showed that the levels
of TRIB3 (Fig. 6E,H,I), LC3II (Fig. 6F,J,K) and cleaved
C3 (Fig. 6G,L,M) were enhanced in these tumours when they had
been treated with GA, supporting the idea that this compound
also induces autophagy-mediated cell death in vivo. Finally, we
investigated whether blockade of the SUMO pathway with GA
affected the activation of RAC1 in theseMDA-MB-231 cell-derived
tumours. When we performed a pulldown assay of RAC1 in extracts
from vehicle and GA-treated tumours, there was less active RAC1 in
the tumours treated with GA (Fig. 6N,O).
Taken together, our findings offer strong support that the
mechanism by which GA inhibits the SUMO pathway, and
negatively regulates tumour survival and invasion in vitro, also
operates in vivo.
DISCUSSION
Normal tissues control the production and release of signalling
molecules in order to maintain their homeostasis and architecture.
The dysregulation of such signals favours tumour progression,
and the proliferation, survival and dissemination of cancer cells
(Hanahan and Weinberg, 2011). SUMOylation is a PTM that alters
the activity of proteins involved in different cellular processes and,
thus, SUMOylation can regulate various biological processes
(Johnson, 2004). Indeed, alterations in the SUMOylation–
deSUMOylation equilibrium have been associated with various
diseases, including cardiac pathologies, neurodegeneration and
cancer (Yang et al., 2017). Here, we explored the importance of the
SUMO1 pathway in controlling tumorigenesis by inhibiting
SUMO1 expression genetically and pharmacologically. Our
findings demonstrate that SUMO1 inhibition negatively regulates
the tumorigenic properties of cancer cells via two different
mechanisms: (1) stimulation of autophagy-mediated cancer cell
death, and (2) inhibition of cancer cell invasiveness via regulation of
RAC1 SUMOylation.
In our work, we used two pharmacological inhibitors of protein
SUMOylation acting through different mechanisms: C15:1 GA and
2D-08. GA is a phenolic acid obtained from leaves, nuts and the
external seed coat ofG. biloba, which exert several pharmacological
effects including inhibition of tumour growth in animal models of
cancer (Baek et al., 2017; Li et al., 2017; Liu et al., 2018b).
Specifically, we used the C15:1 monomer that inhibits protein
SUMOylation by blocking the E1–SUMO1 interaction (Fukuda
et al., 2009).We show that, as with other molecular species (Li et al.,
2017; Liu et al., 2018a,b), the viability of breast and prostate cancer
cells was compromised by GA in a dose-dependent manner.
However, exposure to GA (10 µM) for 24 h impaired the formation
of the SUMO1 complexes without affecting cell viability. Thus, in
these conditions, we could investigate the implication of SUMO
inhibition in tumorigenesis.
In our study, we also used the SUMO E2 inhibitor 2-D08, which
has been shown to block SUMOylation (Choi et al., 2018; Kim
et al., 2014), although GA proved to be a more potent SUMO
inhibitor than 2-D08, producing a 40% reduction in SUMO1-
complexes after 24 h while 2-D08 failed to reduce SUMOylation in
that time. However, after a 48 h exposure to 2-D08, similar
inhibition of SUMOylation was evident as that produced by GA and
a similar degree of autophagy-induced cell death was produced by
both agents.
Findings presented in this work demonstrate by using different
experimental approaches that SUMO1 inhibition induces
autophagy-mediated cancer cell death. Thus, inhibition of
SUMO1 induces the upregulation of several autophagy related
genes such as ATG1, ATG5, ATG7, BECN1 or AMBRA1 at early
time points. Moreover, the genetic depletion of some of this key
autophagy regulatory genes (or the pharmacological inhibition of
autophagy, E64d and pepstatin-A) prevents SUMO1 blockade-
induced apoptosis and cell death. It is worth noting that, unlike
genetic inhibition of SUMO1, the depletion of SUMO2/3 does not
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Fig. 5. RAC1 SUMOylation is required for cell invasion by triple negative breast cancer cells. (A) MDA-MB-231 migration was determined in Boyden
chambers. Migrating cells were determined as the number of GA-treated cells that hadmigrated relative to the vehicle-treated cells (set at 1) after a 24 h treatment.
(B) The migration of MDA-MB-231, assessed as in A, was restricted by SUMO1 depletion. Insets in A and B show representative images of transwells.
(C) Representativewestern blot showing SUMO1-conjugated proteins (nSUMO1) inMDA-MB-231 SUMO1-depleted cells used for migration. (D) Themigration of
MDA-MB-231, assessed as in A, is restricted by UBC9 depletion. (E) Representative western blot of UBC9 levels in MDA-MB-231 UBC9-depleted cells
used for migration. (F) MDA-MB-231 cells were treated with GA for 24 h and RAC activation was assessed by immunoblotting. (G) The Rac-GTP bands from
experiments as shown in F were quantified, and the normalized intensities were calculated relative to the controls. (H) Representative images of MDA-MB-231
cells treated with GA (10 µM) at the times indicated. (I) His–SUMO1 pulldown and RAC1–SUMO1 identification in immunoblots of HeLa cells treated with the
vehicle alone orGA for 24 h. (J) Representative images of cell invasion of indicated cells as assessed in aMatrigel invasion assay. (K) Representativewestern blot
of GFP levels for GFP-, GFP–RAC1- and GFP–SUMO1–RAC1-transfected MDA-MB-231 cells used in the invasion assay. (L) Invasion of MDA-MB-231 cells
transfected with the indicated plasmids and treated with GA for 24 h. (M) Representative images of MDA-MB-231 cells transfected with wild-type GFP–RAC1 or
GFP–SUMO-RAC1 after a 48 h exposure to GA. (N) Proportion of GFP–RAC1 or GFP–SUMO1–RAC1 cells expressing the constructs indicated that
developed lamellipodia-membrane ruffles (‘rescue phenotype’) 48 h after GA treatment. (O) MDA-MB-231 cells were transfected with the plasmids indicated and
24 h later, they were treated with GA (10 µM) for 48 h and cell viability was determined in an MTT assay. All experiments were performed at least three times and
the data are the mean±s.e.m. of three independent experiments. Scale bars: 200 μm. S1, SUMO1. *P≤0.05; n.s., not significant.
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Fig. 6. GA inhibits the growth of subcutaneous MDA-MB-231 cell-derived xenografts. (A) Effect of daily peritumoral injection of GA (10 mg/kg body weight)
on the growth of MDA-MB-231-derived subcutaneous xenografts (mean±s.e.m., n=7 animals for each condition). When the tumours had reached an
average volume of 200 mm3, they were injected peritumorally for 18 days with GA or the vehicle alone, and subjected to the following analysis. The statistical
significance is indicated. *P<0.05. (B) Tumours from vehicle (VEH) and GA xenografts 18 days post-treatment (HE stain). Quantification of the intact tumour
tissue relative to the necrotic and apoptotic areas performed with ImageJ software. Values inside the photomicrographs are expressed as the fraction of intact
tumour tissue relative to the necrotic and apoptotic area. (C) PCNA detection in tumours treated with the vehicle alone or GA (immunofluorescence).
(D) Percentage of PCNA-positive cells per tumour determined in five different treated mice. (E,F) Images of TRIB3 and LC3 levels, and quantification values
obtained using ImageJ software. The values inside the photomicrographs are expressed as the TRIB3 or LC3-stained area relative to the number of nuclei in each
field, and corresponding to 10 fields from three different tumours for each condition. (G) Cleaved caspase-3 (immunofluorescence), where the values inside the
photomicrographs are expressed as the percentage of the cleaved caspase-3-stained cells from three different tumours for each condition. (H) Effect of GA
treatment on TRIB3 expression in tumours analysed in immunoblots. (I) Densitometry quantification of results from H using ImageJ software to analyse 14
different tumours (n=7 vehicle tumours and n=7 GA-treated tumours). (J) Effect of GA on LC3 lipidation in GA-treated tumours analysed by immunoblotting.
(K) Densitometry quantification of results from J using ImageJ software to analyse 14 different tumours (n=7 vehicle tumours and n=7 GA-treated tumours).
(L) Effect of GA on cleaved caspase-3 in GA-treated tumours analysed by immunoblotting. (M) Densitometry quantification of results from L using ImageJ
software to analyse 14 different tumours (n=7 vehicle tumours and n=7 GA-treated tumours). (N) Tumours treated with the vehicle alone or GA, assessing the
activation of RAC (RAC-GTP). (O) Rac-GTP bands were quantified and the normalized intensities were calculated relative to the controls (n=7 tumours per group,
Mann–WhitneyU-test). The data are themeans±s.d.; *P≤0.05; **P≤0.005. For I, K andM, boxes represents the 25–75th percentiles, and themedian is indicated.
The whiskers show the overall range. Scale bars: 200 μm.
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induce autophagy-mediated cell death, suggesting that the effects
observed in this work take place specifically through the blockade
of SUMO1 conjugation.
GA and 2D-08 has been shown to inhibit the SUMO pathways
acting on the E1–SUMO and E2–SUMO enzymes respectively.
However, whether these compounds, and specifically GA, may act on
other targets apart from these SUMO-regulatory enzymes is unknown.
For example, different studies have shown that treatment with GA
inhibits lipogenesis (Ma et al., 2015), and the EGF (Li et al., 2017) and
TGF-β (Baek et al., 2017) signalling pathways, among others.
However, none of these studies investigated whether the changes
observed on those signalling pathways relied on the modulation of
protein SUMOylation. Our results clearly demonstrate that treatment
with GA and 2-D08 inhibits protein SUMOylation in the cellular
models employed in this study; however, it cannot be ruled out that
GA (or 2-D08) may produce their effects at least in part acting
independently of the regulation of protein SUMOylation.
TRIB3 is a member of the Tribbles family of pseudokinases that
has been implicated in autophagy-mediated cancer cell death after
administration of different anti-cancer agents (Salazar et al., 2009a,
b). In our work, we demonstrate that pharmacological or genetic
inhibition of the SUMO pathway induces autophagy, apoptosis and
cell death in a TRIB3-dependent manner. Moreover, we found that
TRIB3, as well as other markers of the autophagy-mediated cell
death pathway, are upregulated in vivo upon GA administration to
mice bearing breast cancer xenografts. However, TRIB3 depletion
partially rescued the decrease in MDA-MB-231 viability evoked by
GA treatment, indicating that there could be additional (TRIB3-
independent) mechanisms by which GA regulates cancer cell death.
RAC1 plays an important role in controlling the cytoskeletal
reorganization associated with cell motility. In a cancer context, the
enhanced activation of this protein has been implicated in metastasis
and invasiveness. Furthermore, RAC1 is SUMOylated by SUMO1
and this modification is required to maintain the activity of the
protein during cell migration (Castillo-Lluva et al., 2010). Here, we
demonstrate that RAC1 SUMOylation is important for optimal
breast tumour cell migration and invasion but not for other RAC1
functions, such as proliferation and survival. GA inhibits the
migration of various tumour cell types (Baek et al., 2017; Hamdoun
and Efferth, 2017; Yang et al., 2014), and we show that this effect on
cell invasion is related to the inhibition of SUMO conjugation.
Overall, the data presented here enhance our understanding of
the mechanisms by which protein SUMOylation regulates cancer
cell biology. Specifically, we found that inhibiting protein
SUMOylation induces autophagic cell death through the
upregulation of the pseudokinase TRIB3, and it impairs cancer
cell invasiveness by inhibiting activation of the small GTPase
RAC1. Blocking the SUMO pathway would reduce RAC1
SUMOylation, thereby diminishing the amount of active RAC1
available to drive the cell migration and invasion programme.
Nevertheless, further studies will be required to fully understand the
mechanisms involved in the induction of autophagy following
the inhibition of SUMOylation. In any case, our findings do support
the notion that blocking protein SUMOylation can be explored as a
potential therapeutic strategy to fight cancer.
MATERIALS AND METHODS
Reagents
Ginkgolic acid C15:1 (#02580585), 2′,3′,4′-trihydroxy-flavone, 2-(2,3,4-
trihydroxyphenyl)-4H-1-Benzopyran-4-one (2-D08; #SML1052), 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; #M5655),
Crystal Violet (#C3886), and the E64d (10 µmol/l; #E8640) and Pepstatin-A
(10 µg/ml; #P5318) inhibitors were all purchased from Sigma-Aldrich
(St Louis, MO). HeLa cells were transfected using LT1 (Mirus Bio,Madison
WI; #MIR 2304) and MDA-MB-231 cells with Lipofectamine 2000
(Thermo Fisher Scientific, Waltham, MA; #11668027). The SUMO1
siRNA (#sc-29498), UBC9 siRNA (#sc-36773), SUMO2/3 siRNA (#sc-
37167), BECLIN1 siRNA (sc-29797), AMBRA1 siRNA (sc-96257) and
TRIB3 shRNA lentiviral particles (#sc-44426-V) were obtained from Santa
Cruz Biotechnology (Heidelberg, Germany). SUMO1 siRNA #2 was from
Sigma-Aldrich (#EHU106621). For siRNA transfection, DharmaFECT
2001 was used (Dharmacon, Lafayette, CO; #T2001).
Protein analyses
Proteins were analysed in western blots as described previously (Castillo-
Lluva et al., 2015). In brief, proteins were extracted from tumours frozen in
RIPA buffer [150 mM NaCl, 1% (v/v) NP40, 50 mM Tris-HCl pH 8.0,
0.1% (v/v) SDS, 1 mM EDTA, 0.5% (w/v) deoxycholate], while proteins
from cell lines were extracted in TNES buffer [100 mM NaCl, 1% (v/v)
NP40, 50 mM Tris-HCl pH 7.6, 20 mM EDTA] containing protease and
phosphatase inhibitor cocktails (Sigma-Aldrich; #P8340). The proteins
recovered were quantified using the BCA Protein Assay Kit (Thermo Fisher
Scientific; #23228), resolved by SDS-PAGE on 4–15% gradient gels
(purchased from Bio-Rad, Berkeley, CA; #456-8085) and transferred to
polyvinylidene difluoride membranes (Immobilon-P, Millipore, Burlington,
MA). The membranes were then probed with the following primary
antibodies: anti-cJUN (1:500; H72, Santa Cruz Biotechnology; #sc-1694),
anti-Bax (1:1000; Cell Signaling Technology; #2772S), anti-TRIB3
(1:1000; Abcam, Cambridge, UK; #ab75846), anti-tubulin (1:1000;
DM1A, Sigma-Aldrich; #T6199), anti-RAC (1:1000; clone 102; BD
Biosciences, Franklin Lakes, NJ), anti-LC3 (1:1000, Sigma-Aldrich;
#L7543), anti-cleaved caspase-3 (1:1000, Cell Signaling Technology;
#9662), anti-GAPDH (1:1000, Sigma-Aldrich; #G8795), anti-cleaved
PARP (1:1000, Cell Signaling Technology; #D214), anti-UBC9 (1:1000,
Abcam; #ab75854), anti-SUMO1 and anti-SUMO2/3 (provided by Ron
Hay’s laboratory, School of Life Sciences, University of Dundee, Dundee,
UK), anti-GFP (Sigma-Aldrich; #SAB1305545), and anti-ATG5 (Cell
Signaling Technology; #12994S). Antibody binding was detected with
horseradish peroxidase (HRP)-conjugated anti-mouse, anti-rabbit or anti-
sheep secondary antibodies (1:10,000 dilution, Bio-Rad), and visualized by
enhanced chemiluminescence (Bio-Rad). The images were obtained with
the ImageQuant LAS 500 chemiluminescence CCD camera (GE Healthcare
Life Sciences, Chicago, Illinois, USA).
Cell culture
MDA-MB-231 and MCF7 breast cancer cells (ATCC) were grown in
complete DMEM, containing 4.5 g/l glucose and L-glutamine (Sigma-
Aldrich). LnCaP and 22Rv1 prostate cancer cells, and BT474 breast cancer
cells (ATCC), were grown in RPMI medium (Sigma-Aldrich). RasV12/T-
large antigen-transformed ATG5+/+ and ATG5−/− cells (Salazar et al.,
2009b) were grown in in DMEM. In all cases, the medium was
supplemented with 56 IU/ml penicillin, 56 mg/l streptomycin (Invitrogen,
Carlsbad, CA) and 10% fetal bovine serum (FBS, LINUS #16sV30180.03),
and the cells were maintained at 37°C in a humid atmosphere containing 5%
CO2. All cells were routinely tested for mycoplasma contamination. Cell
lines were authenticated at the Genomics Core Facility (Instituto de
Investigaciones Biomédicas ‘Alberto Sols’ CSIC-UAM, Madrid, Spain)
using the STR PROFILE DATA, STR amplification kit, GenePrintR 10
System (Promega), STR profile analysis software GeneMapper® v3.7 (Life
Technologies) and the Genomic Analyzer System ABI 3130 XL (Applied
Biosystems). Cell viability was determined in MTT assays following the
manufacturer’s instructions (Sigma-Aldrich; #M5655). For transfection
experiments with SUMO1 and control siRNA, 106 cells were transfected
using the DharmaFECT 1 Transfection Reagent (Dharmacon; #T-2001) and
incubated for up to 72 h before setting up the experiment. Infection with
TRIB3 shRNA human lentiviral particles was performed by using a pool of
concentrated transduction-ready viral particles containing three target
specific shRNAs (or three non-targeted control shRNA) constructs (Santa
Cruz Biotechnology). After the infection of human cancer cell lines, stably
silenced (or control shRNA transduced) cells were selected.
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RAC1 activation and the PAK-PBD pulldown assay
RAC1 activation was determined using a RAC1 activation pulldown assay
(Thermo Fisher Scientific; #16118) following the manufacturer’s
instructions. Cells were treated with 10 µM of GA C15:1 for 24 h before
RAC1 activity was determined.
Boyden chamber cell migration/invasion assay
Cell migration was assayed in Boyden chambers (8.0 μm pore-size
polyethylene terephthalate membrane with a cell-culture insert: VWR,
Radnor, PA; #VWRI734-2744). The cells were trypsinized and counted,
and cell suspensions containing 5×104–10×104 cells in 300 μl of serum-free
medium were added to the upper chamber, with 500 μl of the appropriate
medium added to the lower chamber. The transwell inserts were incubated
for 24 h at 37°C, and the cells on the inside of the transwell inserts were
removed with a cotton swab, whereas those on the underside of the insert
were fixed and stained. Photographs were taken of five random fields and
the cells were counted to calculate the proportion of transmigrated cells.
Boyden chambers with Matrigel (Cell Biolabs, San Diego, CA; #CBA-110)
were used to assay cell invasion.
Immunofluorescence microscopy
MDA-MB-231 cells were plated and grown on glass coverslips for 24 h. The
cells were fixed for 10 min in PBS with 4% paraformaldehyde at room
temperature and the coverslips were then stored in PBS with 0.05% azide
at 4°C until the cells were immunostained. Briefly, the cells were
permeabilized by incubating for 3 min at 4°C in PBS containing 0.5%
Triton X-100 and after that, the coverslips were incubated overnight at 4°C
with a 1:500 dilution of the primary antibodies against Ki67 (Thermo Fisher
Scientific, #PA1-21520), LC3 (Sigma-Aldrich; #L7543) or 1:50 of cleaved
caspase-3 (Asp175; Cell Signaling; #9661). After rinsing thoroughly, the
coverslips were incubated with Alexa Fluor 488 or 594 goat anti-mouse-IgG
or anti-rabbit-IgG secondary antibodies (Invitrogen), counterstained with
DAPI for 30 s, and then mounted on glass slides with DAPI using the Gold
antifade reagent (Invitrogen; #P36935). Immunofluorescence was analysed
under a Zeiss microscope (Zeiss Axioplan 2).
Apoptosis assays
MDA-MB-231 apoptotic cells were quantified using an Annexin V-
fluorescein isothiocyanate (FITC)/propidium iodide (PI) apoptosis detection
kit (Sigma-Aldrich; #APOAF). Cells were seeded at a density of 106 cells in
10 cm dishes. After treatment with 10 µM of GA for 48 h in serum-free
medium, cells were harvested and Annexin-V-FITC/PI labelling was
performed according to the manufacturer’s instructions. The stained cells
were analysed with a flow cytometer (FACSCalibur, BD Biosciences).
Nickel affinity purification
His6–SUMO–1-binding proteins were purified from cell lysates using
nickel-nitrilotriacetic acid agarose (QIAGEN, Hilden, Germany; #30230),
as described previously (Castillo-Lluva et al., 2010).
Xenografts
Tumours were generated in nude mice (Athymic nude-Foxn1 6 weeks old,
ENVIGO RMS, Barcelona, Spain) by subcutaneous injection of 10×106
MDA-MB-231 cells in PBS supplemented with 0.1% glucose. When the
tumours had reached an average volume of 200 mm3, the animals were
randomly assigned to different treatment groups and injected peritumourally
for 18 days with GA (10 mg/kg body weight per day) or the vehicle alone
(ethanol) in 100 µl of PBS, supplemented with 5 mg/ml defatted and
dialyzed BSA. Tumour growth was determined with digital callipers and the
tumour volume was estimated on each day using the formula: tumour
volume=length×width2×0.5. We obtained the tumour growth rate after
transforming the data logarithmically, and we estimated a linear regression
curve for each tumour, evaluating the means of the slopes of these lines for
each group.
This research was carried out in accordance with the regulatory ethical
standards, and in compliance with national and international guidelines, and
it was approved by the authors’ institutional review board.
Statistical analyses
Unless otherwise indicated, the data are expressed as the mean±standard
error of the mean (s.e.m.), and evaluated with the Mann–Whitney U-test or
t-test for two groups, with the Kruskal–Wallis test (followed by Dunn’s
multiple comparison post-test) or by ANOVA (followed by Turkey’s
multiple comparisons test) for more than two groups. The percentage of
positive cells was evaluated using the χ-squared test and the tumour volumes
in the mice were compared using a multiple t-test. For all the analyses,
P-values ≤0.05 were considered statistically significant.
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